- Home
- MRNA vs RNR Comparison
MRNA vs RNR Comparison
Compare MRNA & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- RNR
- Stock Information
- Founded
- MRNA 2010
- RNR 1993
- Country
- MRNA United States
- RNR Bermuda
- Employees
- MRNA N/A
- RNR N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- RNR Property-Casualty Insurers
- Sector
- MRNA Health Care
- RNR Finance
- Exchange
- MRNA Nasdaq
- RNR Nasdaq
- Market Cap
- MRNA 9.8B
- RNR 12.2B
- IPO Year
- MRNA 2018
- RNR 1995
- Fundamental
- Price
- MRNA $24.10
- RNR $267.09
- Analyst Decision
- MRNA Hold
- RNR Hold
- Analyst Count
- MRNA 15
- RNR 14
- Target Price
- MRNA $37.15
- RNR $287.08
- AVG Volume (30 Days)
- MRNA 11.4M
- RNR 510.3K
- Earning Date
- MRNA 11-06-2025
- RNR 10-28-2025
- Dividend Yield
- MRNA N/A
- RNR 0.60%
- EPS Growth
- MRNA N/A
- RNR N/A
- EPS
- MRNA N/A
- RNR 34.70
- Revenue
- MRNA $3,078,000,000.00
- RNR $12,214,870,000.00
- Revenue This Year
- MRNA N/A
- RNR N/A
- Revenue Next Year
- MRNA $11.12
- RNR N/A
- P/E Ratio
- MRNA N/A
- RNR $7.70
- Revenue Growth
- MRNA N/A
- RNR N/A
- 52 Week Low
- MRNA $23.15
- RNR $219.00
- 52 Week High
- MRNA $56.70
- RNR $300.00
- Technical
- Relative Strength Index (RSI)
- MRNA 42.25
- RNR 64.26
- Support Level
- MRNA $23.48
- RNR $251.36
- Resistance Level
- MRNA $29.20
- RNR $246.07
- Average True Range (ATR)
- MRNA 1.50
- RNR 6.49
- MACD
- MRNA -0.36
- RNR 2.20
- Stochastic Oscillator
- MRNA 10.84
- RNR 82.33
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.